Member States shall also include in their MANCPs a dedicated surveillance plan, based on random sampling and testing for a wide range of pharmacologically active substances authorised as veterinary medicinal products or as feed additives and of prohibited or unauthorised pharmacologically active substances and residues thereof which might not be included in the risk-based national plans.
Recital 9, Regulation (EU) 2022/1646
In forcesince 23 Sep 2022